

1-Hydroxy-8-methyl-1,4,8-triazaspiro[4.5]decan-2-one and its (±)-3-methyl homologue: regioselective synthesis and *in vivo* evaluation as adjuvants in leukemia chemotherapy

Igor V. Vystorop,* Nina P. Konovalova, Tat'yana E. Sashenkova, Elena N. Berseneva, Alexander V. Chernyak, Boris S. Fedorov and Remir G. Kostyanovsky

Table S1 Combined activity of cisplatin (CSP) and acids **5** and **6** against P388 leukemia model.

Compound or drug	Times of administration, per day	Single administration doses, in mg kg ⁻¹ body wt.	Increase in average life span, ILS, %	Survived animals, %
CSP	1, 3, 5, 7	0.5	37	0
5	1-7	400	0	0
CSP + 5	1-7+1,3,5,7	0.5 + 400	88	0
CSP	1,3,5,7	0.5	88	0
6	1-7	400	19	0
CSP + 6	1-7+1,3,5,7	0.5 + 400	148	0

Table S2 Combined activity of cyclophosphamide (CPA) and acids **5** and **6** against L1210 leukemia model.

Compound or drug	Times of administration, per day	Single administration doses, in mg kg ⁻¹ body wt.	Increase in average life span, ILS, %	Survived animals, %
CPA	1,6	20	28	12.5
5	1-7	400	0	0
CPA + 5	1-7 + 1,6	20 + 400	35	12.5
CPA	1,6	20	46	0
6	1-7	400	10	0
CPA + 6	1-7 + 1,6	20 + 400	171	0